Additional validation of such improvement thresholds using unblinded trial data may be necessary to allow for more evidence of their utility in clinical research and practice.
Subanalyses of data from the LIBERTY PN-PRIME and LIBERTY PN-PRIME2 studies illustrate how dupilumab for prurigo nodularis can better patient outcomes, including quality of life and symptom burden.